Imint reported net sales of SEK 5.3m in Q3, which thereby was in line with our estimates. Costs were lower than expected, which led to EBIT of SEK -1.4m (vs expected SEK -2.3m).
Read more and download the Research Update: https://goo.gl/igiYfB
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/about/
